Gut microbiome-targeted therapies for Alzheimer’s disease
ABSTRACTThe advent of highthroughput ‘omics’ technologies has improved our knowledge of gut microbiome in human health and disease, including Alzheimer’s disease (AD), a neurodegenerative disorder. Frequent bidirectional communications and mutual regulation exist between the gastrointestinal tract...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2023.2271613 |
| _version_ | 1831878093602553856 |
|---|---|
| author | Tao Zhang Guangqi Gao Lai-Yu Kwok Zhihong Sun |
| author_facet | Tao Zhang Guangqi Gao Lai-Yu Kwok Zhihong Sun |
| author_sort | Tao Zhang |
| collection | DOAJ |
| description | ABSTRACTThe advent of highthroughput ‘omics’ technologies has improved our knowledge of gut microbiome in human health and disease, including Alzheimer’s disease (AD), a neurodegenerative disorder. Frequent bidirectional communications and mutual regulation exist between the gastrointestinal tract and the central nervous system through the gut-brain axis. A large body of research has reported a close association between the gut microbiota and AD development, and restoring a healthy gut microbiota may curb or even improve AD symptoms and progression. Thus, modulation of the gut microbiota has become a novel paradigm for clinical management of AD, and emerging effort has focused on developing potential novel strategies for preventing and/or treating the disease. In this review, we provide an overview of the connection and causal relationship between gut dysbiosis and AD, the mechanisms of gut microbiota in driving AD progression, and the successes and challenges of implementing available gut microbiome-targeted therapies (including probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation) in preventive and/or therapeutic preclinical and clinical intervention studies of AD. Finally, we discuss the future directions in this field. |
| first_indexed | 2024-03-08T04:41:09Z |
| format | Article |
| id | doaj.art-ab002ebb207b40acaba9e63efb6147c1 |
| institution | Directory Open Access Journal |
| issn | 1949-0976 1949-0984 |
| language | English |
| last_indexed | 2025-03-21T21:25:57Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj.art-ab002ebb207b40acaba9e63efb6147c12024-05-28T15:04:40ZengTaylor & Francis GroupGut Microbes1949-09761949-09842023-12-0115210.1080/19490976.2023.2271613Gut microbiome-targeted therapies for Alzheimer’s diseaseTao Zhang0Guangqi Gao1Lai-Yu Kwok2Zhihong Sun3Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, ChinaKey Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, ChinaKey Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, ChinaKey Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University, Hohhot, ChinaABSTRACTThe advent of highthroughput ‘omics’ technologies has improved our knowledge of gut microbiome in human health and disease, including Alzheimer’s disease (AD), a neurodegenerative disorder. Frequent bidirectional communications and mutual regulation exist between the gastrointestinal tract and the central nervous system through the gut-brain axis. A large body of research has reported a close association between the gut microbiota and AD development, and restoring a healthy gut microbiota may curb or even improve AD symptoms and progression. Thus, modulation of the gut microbiota has become a novel paradigm for clinical management of AD, and emerging effort has focused on developing potential novel strategies for preventing and/or treating the disease. In this review, we provide an overview of the connection and causal relationship between gut dysbiosis and AD, the mechanisms of gut microbiota in driving AD progression, and the successes and challenges of implementing available gut microbiome-targeted therapies (including probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation) in preventive and/or therapeutic preclinical and clinical intervention studies of AD. Finally, we discuss the future directions in this field.https://www.tandfonline.com/doi/10.1080/19490976.2023.2271613Gut microbiomeprobioticsprebioticssynbioticspostbioticsfecal microbiota transplantation |
| spellingShingle | Tao Zhang Guangqi Gao Lai-Yu Kwok Zhihong Sun Gut microbiome-targeted therapies for Alzheimer’s disease Gut Microbes Gut microbiome probiotics prebiotics synbiotics postbiotics fecal microbiota transplantation |
| title | Gut microbiome-targeted therapies for Alzheimer’s disease |
| title_full | Gut microbiome-targeted therapies for Alzheimer’s disease |
| title_fullStr | Gut microbiome-targeted therapies for Alzheimer’s disease |
| title_full_unstemmed | Gut microbiome-targeted therapies for Alzheimer’s disease |
| title_short | Gut microbiome-targeted therapies for Alzheimer’s disease |
| title_sort | gut microbiome targeted therapies for alzheimer s disease |
| topic | Gut microbiome probiotics prebiotics synbiotics postbiotics fecal microbiota transplantation |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2023.2271613 |
| work_keys_str_mv | AT taozhang gutmicrobiometargetedtherapiesforalzheimersdisease AT guangqigao gutmicrobiometargetedtherapiesforalzheimersdisease AT laiyukwok gutmicrobiometargetedtherapiesforalzheimersdisease AT zhihongsun gutmicrobiometargetedtherapiesforalzheimersdisease |